A Population-based Assessment of Germline HOXB13 G84E Mutation and Prostate Cancer Risk

Grönberg, 2003, Prostate cancer epidemiology, Lancet, 361, 859, 10.1016/S0140-6736(03)12713-4 Goh, 2012, Genetic variants associated with predisposition to prostate cancer and potential clinical implications, J Intern Med, 271, 353, 10.1111/j.1365-2796.2012.02511.x Aly, 2011, Polygenic risk score improves prostate cancer risk prediction: results from the Stockholm-1 Cohort Study, Eur Urol, 60, 21, 10.1016/j.eururo.2011.01.017 Zheng, 2008, Cumulative association of five genetic variants with prostate cancer, N Engl J Med, 358, 910, 10.1056/NEJMoa075819 Sun, 2011, Inherited genetic markers discovered to date are able to identify a significant number of men at considerably elevated risk for prostate cancer, Prostate, 71, 421, 10.1002/pros.21256 Lindström, 2012, Common genetic variants in prostate cancer risk prediction—results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3), Cancer Epidemiol Biomarkers Prev, 21, 437, 10.1158/1055-9965.EPI-11-1038 Klein, 2012, Evaluation of multiple risk–associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men, Eur Urol, 61, 471, 10.1016/j.eururo.2011.10.047 Ewing, 2012, Germline mutations in HOXB13 and prostate-cancer risk, N Engl J Med, 366, 141, 10.1056/NEJMoa1110000 Adolfsson, 2007, Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005, Scand J Urol Nephrol, 41, 456, 10.1080/00365590701673625 Heidenreich, 2011, EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease, Eur Urol, 59, 61, 10.1016/j.eururo.2010.10.039 NHLBI Exome Sequencing Project. US National Heart, Lung and Blood Institute Web site. http://evs.gs.washington.edu/EVS/. Accessed January 2012. Barrett, 2005, Haploview: analysis and visualization of LD and haplotype maps, Bioinformatics, 21, 263, 10.1093/bioinformatics/bth457 R Development Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2009. Rothman, 2008 Pharoah, 2008, Polygenes, risk prediction, and targeted prevention of breast cancer, N Engl J Med, 358, 2796, 10.1056/NEJMsa0708739 Johns, 2003, A systematic review and meta-analysis of familial prostate cancer risk, BJU Int, 91, 789, 10.1046/j.1464-410X.2003.04232.x Purcell, 2007, PLINK: a tool set for whole-genome association and population-based linkage analyses, Am J Hum Genet, 81, 559, 10.1086/519795 Thompson, 2001, Variation in cancer risks, by mutation position, in BRCA2 mutation carriers, Am J Hum Genet, 68, 410, 10.1086/318181 Thompson, 2002, Cancer incidence in BRCA1 mutation carriers, J Natl Cancer Inst, 94, 1358, 10.1093/jnci/94.18.1358 Tryggvadóttir, 2007, Prostate cancer progression and survival in BRCA2 mutation carriers, J Natl Cancer Inst, 99, 929, 10.1093/jnci/djm005 Thorne, 2011, Decreased prostate cancer-specific survival of men with BRCA2 mutations from multiple breast cancer families, Cancer Prev Res, 4, 1002, 10.1158/1940-6207.CAPR-10-0397 1999, Cancer risks in BRCA2 mutation carriers, J Natl Cancer Inst, 91, 1310, 10.1093/jnci/91.15.1310 Kote-Jarai, 2011, BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients, Br J Cancer, 105, 1230, 10.1038/bjc.2011.383 Sundararajan, 2011, The relevance of BRCA genetics to prostate cancer pathogenesis and treatment, Clin Adv Hematol Oncol, 9, 748 Thompson, 2006, A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers, Cancer Epidemiol Biomarkers Prev, 15, 2542, 10.1158/1055-9965.EPI-06-0687 Pakkanen, 2009, PALB2 variants in hereditary and unselected Finnish prostate cancer cases, J Negat Results Biomed, 8, 12, 10.1186/1477-5751-8-12 Hebbring, 2006, Role of the Nijmegen breakage syndrome 1 gene in familial and sporadic prostate cancer, Cancer Epidemiol Biomarkers Prev, 15, 935, 10.1158/1055-9965.EPI-05-0910